EntrolyticsMD, the world's first imaging platform for digestive diseases has been listed with the FDA. 40 Million people are affected by digestive diseases (including inflammatory bowel disease and GI cancers) costing $119.6 billion in 2018. EntrolyticsMD is already in use across over 300 investigator projects, for AI deployment and in clinical trials.
Here's your TLDR of the announcement ⏱ ⬇️
🕵🏻♀️ What is Entrolytics? A Web-based 'PACS' designed for the assessment and management of digestive diseases.
🤔 What's wrong with regular PACS? They have to support a wide range of clinical domains #neuro , #msk , #oncology etc (a 'horizontal' approach) Entrolytics optimises features for #digestivediseases (a 'vertical' approach).
👥 How many people suffer from digestive diseases? Around 400M people.
This includes #crohnsdisease , #perianaldisease , #ibd subtypes and #cancer
🚀 EntrolyticsMD has already been used in over 300 #research projects, and #clinicaltrials / multicenter trials globally.
🚀 Existing multicenter trials include FIBROTARGET and CAMEO.